Next-gen RNAi drugmaker City prices $200M IPO
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.